SRDX

SRDX

USD

Surmodics Inc. Common Stock

$27.500-0.550 (-1.961%)

वास्तविक समय मूल्य

Healthcare
चिकित्सा उपकरण
संयुक्त राज्य अमेरिका

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$28.050

उच्च

$28.120

कम

$27.400

मात्रा

0.11M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

393.2M

उद्योग

चिकित्सा उपकरण

देश

United States

ट्रेडिंग आँकड़े

औसत मात्रा

0.18M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $26वर्तमान $27.500उच्च $40.39

संबंधित समाचार

BusinessWire

Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations

Analysis of the all-comers PROWL Registry demonstrated high procedural success and safety in a cohort reflecting the real-world complexity of patients with symptomatic limb ischemia, over 40% of whom had symptoms

और देखें
Surmodics Announces Outcomes from 160 Patients in PROWL Registry Evaluating Pounce™ Thrombectomy Platform in Treatment of Real-World Limb Ischemia Presentations
BusinessWire

Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Updated safety and performance data from 160 patients with

और देखें
Surmodics Announces PROWL Registry 160-Patient Data to be Presented in Industry-Sponsored Session at VIVA Conference on November 3
BusinessWire

Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform

Analysis of 160 patients with acute, subacute, or chronic symptoms of thrombotic limb ischemia receiving thromboemboli removal treatment with the Pounce™ Thrombectomy Platform demonstrated high procedural success

और देखें
Surmodics Announces Results from Sex-Specific Analysis of the PROWL Registry Study of Real-World Limb Ischemia Patients Treated with the Pounce™ Thrombectomy Platform
BusinessWire

Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28

PROWL Registry evaluates the Pounce™ Thrombectomy Platform for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature. Results of a sex-specific analysis of 160 patients with

और देखें
Surmodics Announces PROWL Registry Sex-Specific Data to be Presented at TCT Conference on October 28

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।